The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ARTL | -68.79% | -96.21% | -48.01% | -99% |
| S&P | +12.66% | +85.37% | +13.13% | +166% |
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.
No news articles found for Artelo Biosciences.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $6.51M | 80.1% |
| Market Cap / Employee | $1.09M | 0.0% |
| Employees | 6 | 0.0% |
| Net Income | -$3.12M | -175.6% |
| EBITDA | -$3.09M | -158.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.72M | -60.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.04M | -48.7% |
| Short Term Debt | $0.91M | 2588.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -219.08% | -138.5% |
| Return On Invested Capital | -155.59% | -90.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.67M | -328.1% |
| Operating Free Cash Flow | -$3.67M | -328.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.22 | 4.40 | 66.78 | -2.30 | -504.59% |
| Price to Tangible Book Value | 4.75 | 21.06 | -31.39 | -0.94 | -122.76% |
| Enterprise Value to EBITDA | -0.31 | -0.93 | -2.04 | -0.92 | -197.53% |
| Return on Equity | -134.5% | -190.7% | -356.5% | -436.1% | 400.62% |
| Total Debt | $0.10M | $0.10M | $0.88M | $0.95M | 751.79% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
